Splicing inhibition enhances the antitumor immune response through increased tumor antigen presentation and altered MHC-I immunopeptidome
A. Pierson, R. Darrigrand, M. Rouillon, M. Boulpicante, Z. D. Renko, C. Garcia, M. Ghosh, M.-C. Laiguillon, C. Lobry, M. Alami, S. Apcher
This study shows that splicing inhibition with IP2 enhances antitumor immunity by increasing antigen presentation and altering MHC-I immunopeptidomes.
bioRxiv · Jan 6, 2019 · PreprintImmunology